Lupin Ltd — Board/Management Information 2019

Sep 25, 2019

==> picture [169 x 32] intentionally omitted <==

----- Start of picture text ----- Press Release----- End of picture text -----

==> picture [45 x 55] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Appoints Jon Stelzmiller as President of US Specialty Business

Mumbai, Somerset NJ, September 25, 2019: Pharma major Lupin Limited (Lupin) announced the appointment of Jon Stelzmiller as the President of its U.S. Specialty business.

Jon brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas Hart. Jon has a proven track record of building high performing teams and launching 18 major brands across 14 different therapeutic areas including Women’s Health, Oncology and Anti-Infectives. Most recently, Jon was SVP & General Manager — Women’s Healthcare at Bayer where he helped build and lead a billion-dollar women’s health business in the U.S. Prior to Bayer, Jon spent 12 years at Pfizer Inc. in roles of increasing commercial responsibilities in Specialty areas including Institutional sales and market access. Jon spent his early career at The Upjohn Company and Pharmacia Corporation in various sales and sales leadership positions. Jon holds a Bachelor of Science in Bacteriology from North Dakota State University.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, “Jon’s extensive experience in the pharmaceutical industry, particularly in women’s health segment in the U.S., will be a great asset for Lupin as we build our specialty business, including SOLOSEC®. We are delighted to welcome Jon on board.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8[th] largest generics pharmaceutical company by revenues (31[st] Mar 2019, Bloomberg LTM) respectively. The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3[rd] largest Indian pharmaceutical company by global revenues (31[st] Mar 2019, Bloomberg LTM); 5[th] largest generic pharmaceutical player in Japan and 6[th] largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31[st ] March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3[rd] Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries, please contact –

Pooja Thakran

VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66408237

*Safe Harbor Statement